Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine headaches.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Ortho LLC
• Collaborator: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: Almotriptan; Topiramate

Criteria

Inclusion Criteria:

• Have a history of migraine headaches for at least 6 months

• Experience 3-12 migraines per month

• Able to take oral medication

• Able to complete the electronic diary (Personal Digital Assistant-PDA).

Exclusion Criteria:

• You will not be able to participate in the study if you previously discontinued Topiramate or Almotriptan because it did not make you feel better or it made you feel different

• Have 15 or more headache days a month

• Experience migraine aura without a headache

• Already on a migraine preventative medicine.